DEF: Vireo Growth Inc. Sets Date for Annual General Meeting, Outlines Key Proposals

Vireo Growth Inc. will hold its annual general meeting on June 20, 2025, to elect directors and appoint auditors.

Summary

• Vireo Growth Inc. will hold its annual general meeting on June 20, 2025, via live webcast.
• Shareholders will vote on the election of five director nominees and the appointment of Davidson & Company LLP as auditors.
• The board unanimously recommends voting FOR the election of directors and the appointment of auditors.
• The record date for determining shareholders eligible to vote is May 6, 2025.
• As of the record date, there are 339,475,288 subordinate voting shares and 278,100 multiple voting shares outstanding.
• Chicago Atlantic Opportunities, LLC beneficially owns 132,627,754 shares, representing 34.1% of total shares.
• Shareholders can vote by proxy before the meeting via internet, telephone, or mail, with a deadline of June 18, 2025, at 11:59 p.m. Eastern Time.
• The meeting materials are available online at www.proxyvote.com, www.sedarplus.ca, and www.sec.gov.

Sentiment

Score: 6

Explanation: The document is primarily factual and procedural, outlining the details of the upcoming annual general meeting and related proposals. While there are some positive aspects, such as the board's commitment to corporate governance, there are also negative aspects, such as the company's debt and related party transactions. Overall, the sentiment is neutral to slightly positive.

Positives

• The board is committed to sound corporate governance practices.
• The board has determined that three of the five current directors are independent.
• The company has established an Audit Committee and a Nominating, Corporate Governance and Compensation Committee (NCGC Committee).
• The company has a Code of Ethics and Business Conduct that applies to all directors, officers, and employees.
• The company has an insider trading policy designed to promote compliance with insider trading laws.

Negatives

• The company reported late Form 4 filings for several directors and officers in 2024 and 2025.
• The company has engaged in related party transactions with Chicago Atlantic Group, LP, where John Mazarakis is a partner.
• The company has significant debt outstanding under its Credit Facility and 2024 Convertible Notes.
• The company is involved in litigation with Verano, the outcome of which is uncertain.

Risks

• Forward-looking statements are subject to risks, assumptions, estimates, and uncertainties that are difficult to predict.
• The company's business is subject to risks outlined in its Annual Report on Form 10-K.
• The company is involved in litigation with Verano, the outcome of which is uncertain.
• The company's financial performance is dependent on achieving certain AEBITDA and net leverage targets for RSU vesting.

Future Outlook

The circular includes forward-looking statements based on current expectations, estimates, and projections, which are subject to risks and uncertainties.

Management Comments

• Dr. Kingsley's primary goal is to build mainstream, cannabis-based alternatives to opioids, alcohol, and tobacco.
• The Board believes the current leadership structure provides a well-functioning and effective balance between strong management leadership and appropriate oversight by the independent directors.

Industry Context

The document provides insight into the corporate governance and executive compensation practices within the cannabis industry, particularly for companies operating in regulated markets.

Comparison to Industry Standards

• Director compensation is benchmarked against comparable companies to attract and retain qualified individuals.
• Executive compensation includes base salary, long-term equity incentives, and potential bonuses, aligning with industry practices.
• The company's corporate governance practices aim to meet the requirements of both Canadian and U.S. securities regulations.
• The company's reliance on Chicago Atlantic for financing is notable, as they are a major lender in the cannabis industry.
• The company's related party transactions are disclosed and overseen by the Audit Committee, aligning with best practices for transparency.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in litigation with Verano, the outcome of which is uncertain.

Related Party Transactions

• The company has engaged in related party transactions with Chicago Atlantic Group, LP, where John Mazarakis is a partner.
• Prior to his appointment as the Companys Chief Executive Officer, Tyson Macdonald represented Deep Roots in the Deep Roots Merger as a Managing Partner for TrueRise Capital, which provided strategic financial advisory services to Deep Roots in connection with the Deep Roots Merger.

Stakeholder Impact

• Shareholders are asked to vote on key proposals related to the company's governance and financial oversight.
• Executive compensation decisions impact the alignment of management's interests with those of shareholders.
• The company's financial performance and risk management affect the value of shareholder investments.
• The company's legal proceedings could have a material impact on its financial condition and operations.

Next Steps

• Shareholders should review the proxy materials and vote on the proposed resolutions.
• The company will hold its annual general meeting on June 20, 2025.
• The company will continue to monitor and manage its financial performance and risks.
• The company will continue to comply with applicable securities regulations and corporate governance practices.

Key Dates

Keywords

Annual General Meeting, Proxy Statement, Directors, Auditors, Shareholders, Vireo Growth Inc., Corporate Governance, Executive Compensation, Related Party Transactions, Financial Statements